Mounjaro vs Rybelsus: Price & Results Breakdown (2026)

Trying to choose between Mounjaro (Tirzepatide) and Rybelsus (Semaglutide (oral))? Below we put the trial weight loss numbers, monthly cost, dosing, and tolerability head to head — and spell out the type of patient each one tends to fit best.

Quick Answer

Mounjaro (Tirzepatide, Dual GLP-1/GIP receptor agonist) and Rybelsus (Semaglutide (oral), GLP-1 receptor agonist) work through different mechanisms. Mounjaro is FDA-approved for type 2 diabetes with 15-22% of body weight average weight loss at $1,023/mo. Rybelsus is approved for type 2 diabetes with 5-10% of body weight average weight loss at $936/mo.

The Numbers at a Glance

Active Ingredient
Mounjaro
Tirzepatide
Rybelsus
Semaglutide (oral)
Mechanism
Mounjaro
Dual GLP-1/GIP receptor agonist
Rybelsus
GLP-1 receptor agonist
FDA Approved For
Mounjaro
Type 2 diabetes
Rybelsus
Type 2 diabetes
Doses
Mounjaro
2.5mg to 15mg (weekly injection)
Rybelsus
3mg, 7mg, 14mg (daily oral tablet)
Administration
Mounjaro
Weekly subcutaneous injection
Rybelsus
Daily oral tablet on empty stomach
Avg. Weight Loss
Mounjaro
15-22% of body weight
Rybelsus
5-10% of body weight
Monthly Price
Mounjaro
$1,023
Rybelsus
$936
Oral Available
Mounjaro
No
Rybelsus
Yes
Year Approved
Mounjaro
2022
Rybelsus
2019

Figures shown are typical cash-pay prices before insurance. What you pay can differ by pharmacy, region, and your specific plan. Last updated March 2026.

Which Drops More Weight?

Based on clinical data, Mounjaro produces more weight loss on average (15-22% of body weight) compared to Rybelsus (5-10% of body weight). Mounjaro relies on Tirzepatide (Dual GLP-1/GIP receptor agonist), whereas Rybelsus uses Semaglutide (oral) (GLP-1 receptor agonist) — a likely reason for the gap.

Mounjaro
15-22% of body weight
average body weight loss

The earliest medication to combine GLP-1 and GIP receptor activity. Indicated for type 2 diabetes and taken off-label for weight loss, it tends to produce larger reductions than semaglutide on its own.

Rybelsus
5-10% of body weight
average body weight loss

The original GLP-1 medication taken by mouth. Because its dosing runs below injectable semaglutide, weight loss is more modest, but it suits anyone who would rather swallow a tablet than inject.

Which Is Easier on Your Wallet?

At list price, Rybelsus is the more affordable option at $936/month compared to $1,023/month for Mounjaro. That said, what leaves your pocket swings hugely with your coverage. Mounjaro with insurance: $25-$200/month with Lilly savings card. Rybelsus with insurance: $10-$150/month typical copay.

Mounjaro
$1,023/month
With insurance: $25-$200/month with Lilly savings card

Eligible patients may qualify for the Eli Lilly savings card

Rybelsus
$936/month
With insurance: $10-$150/month typical copay

Savings programs from the manufacturer are offered

How the Side Effects Stack Up

Mounjaro (Dual GLP-1/GIP receptor agonist) and Rybelsus (GLP-1 receptor agonist) bring on much the same digestive side effects, which top the list of what patients report:

  • Nausea (most common for both medications)
  • Diarrhea and vomiting
  • Constipation
  • Abdominal pain
  • Decreased appetite
  • Headache, fatigue, dizziness (less common)

Rarer but more serious risks for both drugs include pancreatitis, gallbladder complications, and kidney strain. Each also carries a boxed warning about medullary thyroid carcinoma seen in rodent studies. Go over your complete medical history with a clinician before you start either one.

So Which One Is Right for You?

There is no single winner — the right pick comes down to your diagnosis, what your plan covers, how much weight you want to lose, and how you feel about injections versus pills. Use the quick checklist below as a starting point:

Choose Mounjaro If
  • -You have type 2 diabetes (on-label use, better insurance coverage)
  • -Cost is a concern ($1,023/month at list price)
  • -You want the dual GLP-1/GIP mechanism for potentially greater efficacy
  • -You prefer the convenience of once-weekly dosing
Choose Rybelsus If
  • -You have type 2 diabetes (on-label use, better insurance coverage)
  • -You prefer an oral option over injections
  • -Cost is a concern ($936/month at list price)
  • -You prefer a daily dosing routine

See Who Prescribes These at the Lowest Price

Browse vetted telehealth programs that can prescribe Mounjaro, Rybelsus, and other FDA-approved GLP-1 medications — ranked by what you will actually pay.

Common Questions, Answered

Can I switch from Mounjaro to Rybelsus?

It can be done, but only under a prescriber's guidance, since Mounjaro and Rybelsus rely on different active ingredients (Tirzepatide vs Semaglutide (oral)). Your clinician will set the right starting dose and titration plan for whichever medication you move to.

Which is better for weight loss: Mounjaro or Rybelsus?

Clinical data suggests Mounjaro produces more weight loss on average (15-22% of body weight) compared to Rybelsus (5-10% of body weight). However, individual results vary significantly based on dosing, diet, exercise, and metabolic factors.

Is Mounjaro cheaper than Rybelsus?

At list price, Rybelsus ($936/month) is less expensive than Mounjaro ($1,023/month). With insurance, costs vary significantly. Mounjaro: $25-$200/month with Lilly savings card. Rybelsus: $10-$150/month typical copay.

Do Mounjaro and Rybelsus have the same side effects?

They overlap a lot. Stomach-related effects like nausea, diarrhea, vomiting, and constipation show up with both because they are typical of GLP-1 receptor agonists. That said, the different active ingredients mean how often and how strongly they hit can differ — talk through your history with a clinician to see which is the safer fit for you.

Does insurance cover Mounjaro and Rybelsus?

Coverage varies by plan. Mounjaro is FDA-approved for type 2 diabetes — insurance coverage is typically better for on-label use. Rybelsus is FDA-approved for type 2 diabetes. Check with your specific insurance plan and ask your doctor about prior authorization requirements.